AEON Biopharma (NASDAQ:AEON) Trading Down 2.7% – Here’s What Happened

AEON Biopharma, Inc. (NASDAQ:AEON)’s stock price was down 2.7% on Tuesday . The company traded as low as $0.96 and last traded at $0.98. Approximately 77,797 shares traded hands during trading, a decline of 87% from the average daily volume of 598,428 shares. The stock had previously closed at $1.01.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of AEON Biopharma in a research note on Tuesday, October 1st.

AEON Biopharma Trading Up 3.0 %

The firm’s 50-day moving average price is $0.94 and its 200 day moving average price is $1.89.

AEON Biopharma (NASDAQ:AEON) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. On average, research analysts expect that AEON Biopharma, Inc. will post -0.77 EPS for the current fiscal year.

Institutional Investors Weigh In On AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. Vanguard Group Inc. grew its stake in shares of AEON Biopharma, Inc. (NASDAQ:AEON) by 261.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 758,992 shares of the company’s stock after buying an additional 549,207 shares during the quarter. Vanguard Group Inc. owned about 2.01% of AEON Biopharma worth $8,804,000 as of its most recent filing with the Securities and Exchange Commission. 22.78% of the stock is currently owned by institutional investors.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.